Subject to Revision
Updated June, 2002
PROGRAM DESCRIPTION
The Newfoundland and
Labrador Prescription Drug Program is administered by the Department of
Health and Community Services and comprises two programs, the Senior
Citizens Drug Subsidy Program and the Social Services Drug Program. The
Program also provides coverage for persons who meet financial
eligibility as determined by the Department of Human Resources and
Employment.
OVERVIEW
When a new drug is
introduced to the Canadian market, the manufacturer may submit a request
to NLPDP that it be considered for possible coverage by the Drug
Program. A drug manufacturer may submit a request to NLPDP at any time.
Reviews are conducted in the order they are received and are added as
they are approved. Only drug products which are valid therapeutic
agents, with proven clinical effectiveness will be considered for
coverage under the Program. The cost of therapy and clinical efficacy
relative to other drug therapies is considered; an increased cost may be
justified if the drug produces better clinical results in the patient
population.
Coverage status under
NLPDP is listed under two categories:
1.
OPEN BENEFIT:
(a). Open benefit without
limitations. Drugs listed in this category are available to recipients
without any restrictions. They must however demonstrate:
(b). Open Benefit
with limitations. Drugs listed in this category are available to
recipients providing submissions for reimbursement meet the set
limitations.
2. SPECIAL AUTHORIZATION:
Drugs listed in this
category are available to recipients who meet certain defined criteria.
Request must be made by a physician, dentist, nurse practioner, or
pharmacist on behalf of the patient.
DRUG
REVIEW PROCESS:
Currently the province of
Newfoundland and Labrador in participating in two initiatives related to
the sharing of resources in reviewing submissions for coverage, the
Atlantic Pharmacare Review Committee and the National Common Drug Review
Committee.
INDIVIDUAL PRODUCTS
1. Evidence of approval
from Health Canada - NOC, DIN, Product Monograph.
2. Proposed Drug
Benefit Price and evidence of the manufacturer’s ability to
supply.
3. Clinical data on
therapeutic use, safety and adverse drug reactions.
4. Pharmacoeconomic
evaluation.
5. Letter authorizing
communication with Health Canada, other provinces, territories,
federal drug programs, Patent Medicine Prices Review Board(PMPRB),
expert committees and CCOHTA.
Additional details of
these requirements are supplied in Appendix 1.
-
The new drug
submission is initially screened for completeness by the Secretariat
of the Atlantic Pharmacare Review Committee (APRC). If all
requirements are met, it is placed on the agenda for the next
meeting of the APRC who will prioritize the submission and place it
in the review queue.
-
The APRC Secretariat
will issue a notice of receipt to the manufacturer, referencing the
drug name and the date the submission was received. The letter will
indicate the status of the submission i.e, complete or incomplete.If
a submission is incomplete, the letter will indicate what additional
information is required.
-
The product will be
reviewed based on the priority set by the APRC and, if not already
reviewed by the National Common Drug Review Committee, a reviewer
will be chosen. Once the product review is complete it will be
shared with the four participating provinces and placed on the
agenda for the next Atlantic Expert Committee (AEC) meeting.
-
The EAC will make
recommendations with respect to appropriate criteria for the
cost-effective use of the medication based on the review and each
provincial departmental representative will bring these
recommendations back to their own jurisdiction
-
Our Newfoundland and
Labrador APRC member prepares a summary of the recommendations and
forwards them to the executive committee of the Department of Health
and Community Services. Once a decision is made by the Department
the Pharmaceutical Services Division will notify the manufacuter of
the listing decision.
-
In the case of a
negative decision, issues or concerns raised will be outlined in
this communication. Appeals must contain new evidence-based
supplementary information to address the issues or concerns that
formed the basis of the negative recommendation. Appeals submitted
will be reviewed in the normal process.
-
If the decision is to
list under special authorization the established approval criteria
will be communicated to the manufacturer in their notification
letter from the division.
-
All pharmacy
providers are notified of approved benefits and/or amendments by
NLPDP via web site postings, email and surface mail as appropriate.
All approved benefits are listed on the web site at www.gov.nf.ca/health/nlpdp.
Note: Criteria for drugs designated as requiring special
authorization will be available on the web site.
Appendix 1
Manufacturer Submission
Requirements :
(in
accordance with guidelines set by the Atlantic Pharmacare Review
Committee)
1. Executive Summary (2
copies)
2. Notice of Compliance (NOC)
3. Product Monograph
4.Therapeutic
classifications:
-
American Hospital Formulary Service,
Pharmacologic-Therapeutic
Classification (PTC) and
-
World Health Organization’s Anatomical Therapeutic Chemical (ATC)
classification
|
5. Clinical evidence on
efficacy, effectiveness and safety.
-
Double-blind
randomized, controlled trials (RCTs) published in
peer-reviewed journals are given the most weight
-
If
unpublished/abstract data is submitted, it must be indicated
why it is unpublished.
-
List all
studies submitted in one table and specify the study name,
date, authors and whether it is published or unpublished.
-
Published
articles supporting the validity of outcome measures in
studies (if available)
|
6. Economic Evaluation:
7. Pricing and availability:
8. A letter
authorizing unrestricted communication regarding the drug product
between Nova Scotia, New Brunswick, Prince Edward Island, and
Newfoundland and Labrador drug programs and
-
Other
federal, provincial, and territorial (F/P/T) drug programs
-
F/P/T health
authorities and related facilities
-
Health Canada
-
Patented
Medicine Prices Review Board (PMPRB)
-
Canadian
Coordinating Office for Health Technology Assessment
(CCOHTA)
|
9. A letter
specifying the current or intended Compendium of Pharmaceuticals and
Specialties (CPS) listing status.
10. A copy of the
Pharmaceutical Advertising Advisory Board (PAAB) approved
promotional materials.
Newfoundland
and Labrador Prescription Drug Program
Department of Health and Community Services
P. O. Box 8700
West Block, Confederation Building
St. John’s, NF A1B 4J6
Appendix 2
THERAPEUTIC CLASS REVIEWS
Many new drugs released
to the market are similar in classification and are intended for
treatment of a specific disease state. As such, therapuetic class
reviews are often conducted and involve extensive consultation via ad
hoc therapeutic class review committees, comprising members with
expertise in the treatment of the disease for which the drugs are
intended.
Reviews are conducted
with emphasis on clinical literature such as reports of scientific
studies comparing the new product with existing therapeutic
alternatives. Material discussed include utilization data from the Drug
Program, information available from other provincial drug programs,
Federal Provincial Territorial (FTP) agencies, as well as scientific and
clinical literature pertaining to the drug and drug category. If there
are no significant additional clinical benefits, decisions will be made
by the department based on the comparative costs of available therapies.
The Drug Program also
utilizes data from the Patient Research Center at Memorial University as
a source of reference when making decisions with respect to coverage
status. This information includes cost benefit analysis of a drug
product to determine effectiveness in real life situations versus
controlled clinical trials.
|